ARTH · Arch Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.9K | $31.9K | $45.9K | $6.3K | $3.1K | $6.3K | - | - | - | $0 |
| Cost of Revenue | $21.1K | $21.6K | $23.6K | $18.5K | $18.7K | $17.6K | $17.1K | $17.4K | $0 | $0 |
| Gross Profit | $9.8K | $10.3K | $22.3K | ($12.3K) | ($15.6K) | ($11.4K) | - | - | - | $0 |
| R&D | $155.7K | $203.9K | $205.6K | $139.0K | $170.6K | $161.5K | $159.8K | $527.7K | $234.6K | $297.6K |
| SG&A | $875.6K | $683.2K | $1.31M | $870.1K | $1.25M | $1.10M | $836.2K | $1.21M | $1.26M | $854.6K |
| Total Operating Expenses | $1.05M | $908.6K | $1.54M | $1.03M | $1.44M | $1.28M | $1.01M | $1.75M | $1.23M | $1.67M |
| D&A | - | - | $650 | $273 | $380 | $663 | $799 | $799 | $799 | $799 |
| Operating Income | ($1.02M) | ($876.7K) | ($1.49M) | ($1.01M) | ($1.43M) | ($1.28M) | ($1.01M) | ($1.75M) | ($1.51M) | ($1.67M) |
| Interest Expense | $671.9K | $592.4K | $1.19M | $808.8K | $635.2K | $524.3K | $39.9K | $39.5K | $29.3K | $40.2K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($5.65M) | ($1.47M) | ($2.68M) | ($1.82M) | ($902.5K) | ($1.80M) | ($1.05M) | ($790.3K) | ($1.55M) | ($1.53M) |
| EPS - Basic | ($1.44) | ($0.33) | ($0.57) | ($1.42) | ($0.71) | ($1.31) | $0.00 | ($0.01) | - | - |
| EPS - Diluted | ($1.42) | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $30.0K | $26.4K | $205.8K | $222.7K | $29.5K | $10.6K | $746.9K | $54.4K | $1.09M | $2.27M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $1.32M | $1.33M | $1.34M | $1.36M | $1.40M | $1.41M | $1.41M | $1.20M | $1.09M | $1.09M |
| Accounts Payable | $2.92M | $2.97M | $2.77M | $2.30M | $2.43M | $1.76M | $1.33M | $1.29M | $748.9K | $408.1K |
| Current Assets | $1.39M | $1.53M | $1.81M | $1.95M | $1.59M | $1.71M | $2.60M | $1.43M | $2.54M | $3.67M |
| Total Assets | $1.40M | $1.54M | $1.82M | $1.96M | $1.59M | $1.72M | $2.60M | $1.44M | $2.54M | $3.68M |
| Current Liabilities | $13.96M | $12.42M | $11.40M | $9.47M | $7.98M | $4.15M | $3.32M | $1.44M | $1.95M | $1.73M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | $0 |
| Total Liabilities | - | - | - | $9.47M | $7.98M | $7.60M | $6.80M | $4.50M | $4.97M | $4.70M |
| Stockholders' Equity | ($12.56M) | ($10.88M) | ($9.58M) | ($7.51M) | ($6.39M) | ($5.89M) | ($4.19M) | ($3.06M) | ($2.42M) | ($1.03M) |
| Retained Earnings | ($72.59M) | ($66.21M) | ($64.74M) | ($62.06M) | ($57.78M) | ($56.87M) | ($55.07M) | ($52.14M) | ($51.35M) | ($49.80M) |
Cash Flow
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($862.6K) | - | - | ($650.1K) | - | - | ($1.18M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | $845.7K | - | - | ($86.3K) | - | - | $0 | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 31.8% | 32.4% | 48.5% | -195.9% | -498.0% | -181.7% | - | - | - | - |
| Operating margin | -3304.4% | -2751.3% | -3258.7% | -16200.9% | -45542.6% | -20376.0% | - | - | - | - |
| EBITDA margin | - | - | -3257.3% | -16196.5% | -45530.5% | -20365.4% | - | - | - | - |
| Net margin | -18292.2% | -4610.4% | -5846.6% | -29118.5% | -28833.1% | -28750.3% | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 503.6% | 639.8% | 448.2% | 2220.9% | 5451.6% | 2578.7% | - | - | - | - |
| SG&A / Revenue | 2832.6% | 2143.9% | 2859.0% | 13896.4% | 40025.1% | 17615.7% | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -404.6% | -95.4% | -147.2% | -93.1% | -56.7% | -104.9% | -40.2% | -54.9% | -60.9% | -41.6% |
| Return on equity | 45.0% | 13.5% | 28.0% | 24.3% | 14.1% | 30.6% | 25.0% | 25.8% | 64.0% | 149.2% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.10 | 0.12 | 0.16 | 0.21 | 0.20 | 0.41 | 0.78 | 0.99 | 1.30 | 2.12 |
| Quick ratio | 0.01 | 0.02 | 0.04 | 0.06 | 0.02 | 0.07 | 0.36 | 0.16 | 0.74 | 1.49 |
| Cash ratio | 0.00 | 0.00 | 0.02 | 0.02 | 0.00 | 0.00 | 0.22 | 0.04 | 0.56 | 1.31 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00 |
| Debt / Assets | - | - | - | - | - | - | - | - | - | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -1.5x | -1.5x | -1.3x | -1.3x | -2.2x | -2.4x | -25.2x | -44.4x | -51.6x | -41.5x |
| Equity multiplier | -0.11 | -0.14 | -0.19 | -0.26 | -0.25 | -0.29 | -0.62 | -0.47 | -1.05 | -3.58 |
| Liabilities / Assets | - | - | - | 4.83 | 5.01 | 4.43 | 2.61 | 3.13 | 1.95 | 1.28 |
| Efficiency | ||||||||||
| Asset turnover | 0.02 | 0.02 | 0.03 | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 |
| Inventory turnover | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 22862d | 22515d | 20655d | 26879d | 27346d | 29217d | 30129d | 25078d | - | - |
| Days payable outstanding | 50504d | 50284d | 42868d | 45390d | 47305d | 36458d | 28280d | 26974d | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 393.7% | 918.1% | 632.6% | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | 47.2% | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -0.7% | 38.5% | -17.2% | -0.7% | 18.6% | 15.5% | 39.6% | -0.0% | -19.5% | -34.3% |
| Net income growth (YoY) | -210.2% | -62.8% | -49.0% | -74.2% | -14.2% | -16.1% | 31.6% | 55.9% | -34.3% | -69.2% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -67.3% | -70.3% | -62.6% | -79.1% | -108.7% | -143.0% | -308.8% | - | 5.7% | 31.6% |
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Arch Therapeutics against the 5 most active filers in the same SIC group.